Think Next.

Use 4D biology to discover, develop, de‑risk and design, so better treatments reach patients sooner.Use 4D biology to discover, develop, de‑risk and design, so better treatments reach patients sooner.

See how it works

The difference

~90% of drug candidates that enter clinical trials never reach patients. Many fail because early lab models don’t fully capture how cells behave in the human body.Source: Humane Society International, Drug Discovery Today, 2018

Better data means faster, more accurate predictions.

Cells never sit still and look different from every angle. We observe their response to treatment candidates in 3D over time.Cells never sit still and look different from every angle. We observe their response to treatment candidates in 3D over time.

Platform

One continuous loop, refined with every turn.

  1. See

    Observe how living cells respond to treatments in 3D over time.

    ATLAS: our own imaging library of 500M+ cancer cells.

    ATLAS · imaging libraryATLAS

    1. 3D, over timeEvery cell is imaged slice by slice, stacked into a complete 3D view and tracked over time.
    2. Any therapeutic modalitysiRNAs, ADCs, peptides, small molecules and more: we observe how each one changes cell behaviour.
    3. Single-cell to populationOur models analyse 2D, 3D and time-lapse images at both scales to predict how cells will respond next.
  2. Predict

    Turn how cells behave into what they'll do next.

    FORM turns around 300 hours of lab work into around six hours of compute.FORM turns ~300 hours of lab work into ~6 hours of compute.

    See how our models work

    • Read single cells for signs of how well an asset will work
    • Simulate how cells are likely to change shape after treatmentSimulate how cells change shape after treatment
    • Map how cell shape connects to genetics and biochemistryLink cell shape to genetics and biochemistry
    • Combine imaging with protein data to infer mechanism, pathways and early toxicity
  3. Act

    Put the predictions to work, wherever you are in development.

    Sentinal4D works with partners across the whole journey, from the first target to the clinic.We work with partners from first target to clinic.

    See it in action

    • DiscoverFind new assets and targets in your area of interest.
    • DevelopUnderstand how an asset works: its mechanism, off-target effects and optimal dosing.
    • De-riskPredict how an asset is likely to perform across different cell types and genetic backgrounds.Predict how an asset will perform across cell types and genetic backgrounds.
    • DesignMatch treatments to the patients most likely to benefit.
  4. Learn

    We test our predictions against real outcomes in the lab, so the models keep improving.We test predictions against real lab outcomes, so the models keep improving.

    • For pharma and biotech companiesStronger assets prioritised earlier so teams can decide with more confidence.
    • For patientsRicher biological evidence earlier, to support more personalised treatment decisions.
    • For what comes nextThe next generation of AI for biology with value that grows as the data, models and evidence grow.

See how it works

In partnership with
  • The Institute of Cancer Research (ICR)
  • Stevenage Bioscience Catalyst
  • Lightning AI
  • For pharma and biotech companies

    Stronger assets prioritised earlier so teams can decide with more confidence.

  • For patients

    Richer biological evidence earlier, to support more personalised treatment decisions.

  • For what comes next

    The next generation of AI for biology with value that grows as the data, models and evidence grow.

Case studies

Proven in oncology today, growing across biology as evidence and insight build.Proven in oncology today, growing across biology as evidence builds.

Models

    Rigorously benchmarked

    Our models are tested against established methods and published in leading peer-reviewed journals and conferences, including NeurIPS, Cell Systems, ICCV and MICCAI. Our core methods are patent-pending, with positive international reviews and filings in Europe and the US.

    We publish to share our advances. Our best-performing models stay in-house.

    • NeurIPS
    • Cell Systems
    • ICCV
    • MICCAI
    • Science
    • ICML

      About

      Sentinal4D was founded by Chris Bakal, Matt De Vries and Vicky Bousgouni to build biologically informed AI. Spun out from the Institute of Cancer Research to form an integrated team of biologists and AI developers.Chris Bakal, Matt De Vries and Vicky Bousgouni founded Sentinal4D to build biologically informed AI. Spun out of The Institute of Cancer Research, we are an integrated team of biologists and AI developers.

      “[Placeholder] A short pull quote from the founder interview will sit here.”

      Chris Bakal, CEO & Co-Founder
      Co-founder interview Chris Bakal, Matt De Vries and Vicky Bousgouni

      Sentinal4D Team

      • Chris Bakal, CEO and Co-Founder

        Chris Bakal

        CEO & Co-Founder

      • Matt De Vries, CTO and Co-Founder

        Matt De Vries

        CTO & Co-Founder

      • Vicky Bousgouni, COO and Co-Founder

        Vicky Bousgouni

        COO & Co-Founder

      • Reed Naidoo, AI Research Scientist

        Reed Naidoo

        AI Research Scientist

      • Georgios Skiadas, Biology Research Scientist

        Georgios Skiadas

        Biology Research Scientist

      • Ugur Moustafa, Computational Intern

        Ugur Moustafa

        Computational Intern

      • Sunny Park, Communications

        Sunny Park

        Communications

      Board of Directors

      • Amritha Nair, Board of Directors, The Institute of Cancer Research

        Amritha Nair

        The Institute of Cancer Research

      • Jonathan Chevallier, Board of Directors

        Jonathan Chevallier

        Board Director

      • Katie Lockwood, Board of Directors, Twin Path Ventures

        Katie Lockwood

        Twin Path Ventures

      Scientific Advisory Board

      • Prof. Vicky Sanz-Moreno, Scientific Advisory Board, The Institute of Cancer Research

        Prof. Vicky Sanz-Moreno

        The Institute of Cancer Research

      Backed by

      • Twin Path Ventures
      • Arben Ventures
      • Innovate UK
      • NVIDIA
      • Google Cloud for Startups
      • Cancer Tech Accelerator
      • Cancer Research Horizons

      Get in touch

      Partner with us

      Email us at and we'll be in touch.

      Investors

      Email us at and we'll be in touch.

      Join the team

      Email us at and we'll be in touch.